Handelsbanken Fonder AB Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Handelsbanken Fonder AB lowered its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLDGet Rating) by 37.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,841 shares of the biopharmaceutical company’s stock after selling 18,200 shares during the period. Handelsbanken Fonder AB’s holdings in Amicus Therapeutics were worth $312,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Amicus Therapeutics during the third quarter valued at approximately $27,000. First Horizon Advisors Inc. acquired a new stake in shares of Amicus Therapeutics during the second quarter worth approximately $29,000. Lazard Asset Management LLC grew its position in shares of Amicus Therapeutics by 68.0% during the second quarter. Lazard Asset Management LLC now owns 9,837 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 3,981 shares in the last quarter. Strs Ohio acquired a new stake in shares of Amicus Therapeutics during the second quarter worth approximately $122,000. Finally, Assetmark Inc. grew its position in shares of Amicus Therapeutics by 353.0% during the second quarter. Assetmark Inc. now owns 12,027 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 9,372 shares in the last quarter.

Insider Activity

In other news, Chairman John F. Crowley sold 10,468 shares of the business’s stock in a transaction on Monday, October 17th. The shares were sold at an average price of $10.90, for a total transaction of $114,101.20. Following the completion of the transaction, the chairman now owns 835,083 shares of the company’s stock, valued at $9,102,404.70. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Bradley L. Campbell sold 5,470 shares of the business’s stock in a transaction on Tuesday, November 1st. The shares were sold at an average price of $10.01, for a total transaction of $54,754.70. Following the completion of the transaction, the chief executive officer now owns 689,618 shares of the company’s stock, valued at $6,903,076.18. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman John F. Crowley sold 10,468 shares of the business’s stock in a transaction on Monday, October 17th. The shares were sold at an average price of $10.90, for a total transaction of $114,101.20. Following the transaction, the chairman now directly owns 835,083 shares of the company’s stock, valued at approximately $9,102,404.70. The disclosure for this sale can be found here. Over the last quarter, insiders sold 191,854 shares of company stock valued at $2,204,236. 2.40% of the stock is currently owned by company insiders.

Amicus Therapeutics Stock Performance

Amicus Therapeutics stock opened at $12.02 on Thursday. The company has a market cap of $3.38 billion, a PE ratio of -13.07 and a beta of 0.88. The company has a fifty day moving average price of $11.64 and a two-hundred day moving average price of $11.23. The company has a debt-to-equity ratio of 2.95, a current ratio of 2.78 and a quick ratio of 2.70. Amicus Therapeutics, Inc. has a 12 month low of $5.91 and a 12 month high of $12.96.

Amicus Therapeutics (NASDAQ:FOLDGet Rating) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.07. The firm had revenue of $81.69 million during the quarter, compared to the consensus estimate of $84.55 million. Amicus Therapeutics had a negative net margin of 81.65% and a negative return on equity of 123.94%. Research analysts expect that Amicus Therapeutics, Inc. will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on FOLD. StockNews.com raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 31st. Morgan Stanley raised their price target on shares of Amicus Therapeutics from $14.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 8th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.67.

Amicus Therapeutics Profile

(Get Rating)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.

Recommended Stories

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.